NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.23. The biopharmaceutical company earned $43.59 million during the quarter, compared to the consensus estimate of $43.30 million. Vanda Pharmaceuticals had a negative net margin of 2.84% and a negative return on equity of 3.06%. The firm's revenue for the quarter was up 16.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.11) earnings per share. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Vanda Pharmaceuticals.

6 equities research analysts have issued twelve-month target prices for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $27.00. On average, they anticipate Vanda Pharmaceuticals' share price to reach $23.00 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Some companies that are related to Vanda Pharmaceuticals include Array Biopharma (ARRY), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Horizon Pharma (HZNP), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), The Medicines (MDCO), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Evotec (EVTCY), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA) and Clovis Oncology (CLVS).

Media headlines about VNDA stock have been trending somewhat positive on Tuesday, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a daily sentiment score of 0.17 on Accern's scale. They also assigned news headlines about the biopharmaceutical company an impact score of 47.14 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

Vanda Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.19%), venBio Select Advisor LLC (5.33%), Rothschild Asset Management Inc. (2.60%), Millennium Management LLC (1.91%), Prudential Financial Inc. (1.63%) and Northern Trust Corp (1.12%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

VNDA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., PNC Financial Services Group Inc., Millennium Management LLC, Spark Investment Management LLC, Cortina Asset Management LLC, Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

VNDA stock was purchased by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Hawk Ridge Capital Management LP, Alambic Investment Management L.P., Prudential Financial Inc., A.R.T. Advisors LLC, Russell Investments Group Ltd., UBS Group AG and Swiss National Bank. View Insider Buying and Selling for Vanda Pharmaceuticals.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $19.05.

Vanda Pharmaceuticals has a market capitalization of $977.08 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]